4,799 Shares in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) Purchased by B. Metzler seel. Sohn & Co. Holding AG

B. Metzler seel. Sohn & Co. Holding AG bought a new stake in shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor bought 4,799 shares of the company's stock, valued at approximately $553,000.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Ashton Thomas Private Wealth LLC bought a new position in Neurocrine Biosciences during the second quarter valued at $28,000. Innealta Capital LLC bought a new stake in Neurocrine Biosciences in the second quarter worth about $30,000. New Covenant Trust Company N.A. purchased a new position in shares of Neurocrine Biosciences during the first quarter valued at approximately $32,000. EdgeRock Capital LLC bought a new position in shares of Neurocrine Biosciences during the second quarter valued at approximately $35,000. Finally, Blue Trust Inc. raised its holdings in shares of Neurocrine Biosciences by 171.9% in the third quarter. Blue Trust Inc. now owns 348 shares of the company's stock worth $40,000 after buying an additional 220 shares during the period. Hedge funds and other institutional investors own 92.59% of the company's stock.

Neurocrine Biosciences Stock Up 1.2 %

Shares of NBIX traded up $1.46 during mid-day trading on Monday, reaching $127.11. The company had a trading volume of 1,563,582 shares, compared to its average volume of 877,466. The stock has a market capitalization of $12.87 billion, a P/E ratio of 33.69 and a beta of 0.35. Neurocrine Biosciences, Inc. has a 52-week low of $110.52 and a 52-week high of $157.98. The stock has a 50 day moving average of $118.62 and a two-hundred day moving average of $131.89.

Analyst Ratings Changes

Several research firms recently commented on NBIX. Piper Sandler raised shares of Neurocrine Biosciences from a "neutral" rating to an "overweight" rating and raised their price target for the stock from $131.00 to $159.00 in a research note on Thursday, August 29th. Cantor Fitzgerald restated an "overweight" rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a report on Monday, September 16th. Royal Bank of Canada decreased their target price on Neurocrine Biosciences from $136.00 to $133.00 and set a "sector perform" rating for the company in a research report on Friday, October 4th. Barclays dropped their price target on Neurocrine Biosciences from $180.00 to $160.00 and set an "overweight" rating on the stock in a research report on Monday, September 9th. Finally, Citigroup lifted their price objective on Neurocrine Biosciences from $150.00 to $158.00 and gave the company a "neutral" rating in a report on Friday, August 2nd. Five equities research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, Neurocrine Biosciences presently has an average rating of "Moderate Buy" and a consensus price target of $163.91.

Neurocrine Biosciences Company Profile

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.